Title |
Role of TET2 Mutations in Myeloproliferative Neoplasms
|
---|---|
Published in |
Current Hematologic Malignancy Reports, December 2011
|
DOI | 10.1007/s11899-011-0108-8 |
Pubmed ID | |
Authors |
Elodie Pronier, François Delhommeau |
Abstract |
Recently, 5-hydroxymethylcytosine (5-hmC), the 6th base of DNA, was discovered as the product of the hydroxylation of 5-methylcytosine (5-mC) by the ten-eleven translocation (TET) oncogene family members. One of them, TET oncogene family member 2 (TET2), is mutated in a variety of myeloid malignancies, including in 15% of myeloproliferative neoplasms (MPNs). Recent studies tried to go further into the biological and epigenetic function of TET2 protein and 5-hmC marks in the pathogenesis of myeloid malignancies. Although its precise function remains partially unknown, TET2 appears to be an important regulator of hematopoietic stem cell biology. In both mouse and human cells, its inactivation leads to a dramatic deregulation of hematopoiesis that ultimately triggers blood malignancies. Understanding this leukemogenic process will provide tools to develop new epigenetic therapies against blood cancers. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Brazil | 2 | 5% |
Denmark | 1 | 3% |
United States | 1 | 3% |
Unknown | 35 | 90% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 13 | 33% |
Researcher | 8 | 21% |
Other | 3 | 8% |
Student > Bachelor | 3 | 8% |
Student > Master | 3 | 8% |
Other | 7 | 18% |
Unknown | 2 | 5% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 19 | 49% |
Medicine and Dentistry | 8 | 21% |
Biochemistry, Genetics and Molecular Biology | 6 | 15% |
Unspecified | 1 | 3% |
Social Sciences | 1 | 3% |
Other | 1 | 3% |
Unknown | 3 | 8% |